BioSpace News Archive

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that is has received clearance from the U.S. Food & Drug Administration (FDA) to market SImpact SI Joint Fixation System for Posterior-Oblique approaches.

Photocure ASA announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present corporate overviews and host 1-on-1 meetings with investors at the DNB Small & Medium Enterprises Conference on April 7, 2022, and the 21st Annual Needham Healthcare Conference being held virtually April 11-14, 2022.

The new funds will go to support development of the FiCAT platform prototype and preclinical validation with in vivo and ex vivo models.

Partner Therapeutics, Inc., a commercial biotech company, announces publication of results from investigator-sponsored pre-clinical research evaluating use of recombinant murine GM-CSF to improve cognitive ability and brain pathology in an aged mouse model of Down syndrome and in aged normal mice.

According to Report, the global dental services market garnered revenue around US$ 298 Billion in 2020 and to reach over US$ 530 Billion by 2027 and expanding growth at a CAGR of 6% from 2021 to 2027.

DNA diagnostics technique enables healthcare professionals and medical experts to identify various diseases, including cancer, infectious diseases, and myogenic disorders, and to discover the convinient treatment for the same.

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2021 and full-year 2021 financial and operating results and provided a business update.

Pardes Biosciences, Inc. (NASDAQ: PRDS), today reported financial results for the full year ended December 31, 2021 and provided a business update.

BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, for NX-1607 in the treatment of patients with advanced solid tumors.